ALIMERA SCIENCES INC
DelistedCIK 1267602fmd_05ZM55S1AEZDY9ZWF9JQJC30Q7Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Jun 30, 2024, 58 periods
Latest annual · FY2023
Millions- Total revenues
- 81
- Gross profit
- 70
- Operating income
- (2)
- Net income
- (20)
- Free cash flow
- (15)
Latest quarter · Q2 FY2024
Millions- Total revenues
- 27
- Gross profit
- 23
- Operating income
- (0)
- Net income
- (3)
- Free cash flow
- 1
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2020 to FY2023
- +16.7%
- Revenue, 5 yearsFY2018 to FY2023
- +11.6%
- Net income, 5 yearsFY2018 to FY2023
- n/m
ALIMERA SCIENCES INC financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $80.8 million | $54.1 million | +49.2% | 10-K 2024-03-08 · proof |
| Gross profit | $69.9 million | $46.2 million | +51.5% | 10-K 2024-03-08 · proof |
| Operating income | -$1.9 million | -$11.6 million | 10-K 2024-03-08 · proof | |
| Net income | -$20.1 million | -$18.1 million | 10-K 2024-03-08 · proof | |
| Cash from operating activities | -$14.3 million | -$10 million | 10-K 2024-03-08 · proof | |
| Free cash flow | -$14.5 million | -$10.2 million | 10-K 2024-03-08 · proof | |
| Total assets | $153.5 million | $42.6 million | +260.4% | 10-K 2024-03-08 · proof |
| Total liabilities | $107.4 million | $63.4 million | +69.3% | 10-K 2024-03-08 · proof |
| Cash and cash equivalents | $12.1 million | $5.3 million | +128.6% | 10-K 2024-03-08 · proof |
- What was ALIMERA SCIENCES INC's revenue in fiscal 2023?
- ALIMERA SCIENCES INC reported revenue of $80.8 million for fiscal 2023 (the year ended Dec 31, 2023), against $54.1 million the year before (+49.2%). Source: the 10-K filed with the SEC on Mar 8, 2024. SEC
- What was ALIMERA SCIENCES INC's gross profit in fiscal 2023?
- ALIMERA SCIENCES INC reported gross profit of $69.9 million for fiscal 2023 (the year ended Dec 31, 2023), against $46.2 million the year before (+51.5%). Source: the 10-K filed with the SEC on Mar 8, 2024. SEC
- What was ALIMERA SCIENCES INC's operating income in fiscal 2023?
- ALIMERA SCIENCES INC reported operating income of -$1.9 million for fiscal 2023 (the year ended Dec 31, 2023), against -$11.6 million the year before. Source: the 10-K filed with the SEC on Mar 8, 2024. SEC
- What was ALIMERA SCIENCES INC's net income in fiscal 2023?
- ALIMERA SCIENCES INC reported net income of -$20.1 million for fiscal 2023 (the year ended Dec 31, 2023), against -$18.1 million the year before. Source: the 10-K filed with the SEC on Mar 8, 2024. SEC
- What was ALIMERA SCIENCES INC's cash from operating activities in fiscal 2023?
- ALIMERA SCIENCES INC reported cash from operating activities of -$14.3 million for fiscal 2023 (the year ended Dec 31, 2023), against -$10 million the year before. Source: the 10-K filed with the SEC on Mar 8, 2024. SEC
- What was ALIMERA SCIENCES INC's free cash flow in fiscal 2023?
- ALIMERA SCIENCES INC reported free cash flow of -$14.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$10.2 million the year before. Source: the 10-K filed with the SEC on Mar 8, 2024. SEC
- What are ALIMERA SCIENCES INC's total assets?
- As of Dec 31, 2023, ALIMERA SCIENCES INC reported total assets of $153.5 million, against $42.6 million a year earlier (+260.4%). Source: the 10-K filed with the SEC on Mar 8, 2024. SEC
- What are ALIMERA SCIENCES INC's total liabilities?
- As of Dec 31, 2023, ALIMERA SCIENCES INC reported total liabilities of $107.4 million, against $63.4 million a year earlier (+69.3%). Source: the 10-K filed with the SEC on Mar 8, 2024. SEC
- What are ALIMERA SCIENCES INC's cash and cash equivalents?
- As of Dec 31, 2023, ALIMERA SCIENCES INC reported cash and cash equivalents of $12.1 million, against $5.3 million a year earlier (+128.6%). Source: the 10-K filed with the SEC on Mar 8, 2024. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1267602&period_type=annual&limit=5"Information only, not investment advice.